Semaglutide vs Tirzepatide: Which Is Right for You?
Verdict Summary
Tirzepatide produces greater average weight loss in clinical trials. Semaglutide has a longer post-market safety record. Both are excellent options.
Medical Disclaimer: This comparison is for educational purposes only. Consult a healthcare provider before starting any peptide protocol. Full disclaimer →
At a Glance
| Dimension | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | Dual GIP + GLP-1 receptor agonist |
| Average Weight Loss | 10–15% body weight | 15–22.5% body weight |
| Half-Life | ~7 days | ~5 days |
| Dosing | Weekly injection | Weekly injection |
| FDA Approval | Ozempic (T2D), Wegovy (obesity) | Mounjaro (T2D), Zepbound (obesity) |
| Market Availability | Longer track record | Newer, growing availability |
| Cost (approx.) | $200–$1,200/month brand | $250–$1,300/month brand |
Semaglutide Deep Dive
Semaglutide is a GLP-1 receptor agonist that reduces appetite through hypothalamic GLP-1 receptor activation, slows gastric emptying to prolong satiety, and improves insulin secretion. The STEP trial program demonstrated 10–15% average body weight reduction at 2.4 mg weekly. Semaglutide has a longer post-market safety record than Tirzepatide, with cardiovascular outcome data from the SELECT trial showing significant reductions in major adverse cardiovascular events.
Tirzepatide Deep Dive
Tirzepatide adds GIP receptor agonism to GLP-1 receptor activation, producing additive effects on appetite suppression and fat mobilization. The SURMOUNT trial program demonstrated 15–22.5% average body weight reduction at 15 mg weekly — significantly exceeding Semaglutide's outcomes. The dual mechanism appears to produce superior results in adipose tissue specifically, potentially explaining the greater weight loss.
How to Choose
Choose Semaglutide if…
- •You want the longer post-market safety record
- •You have cardiovascular disease (SELECT trial data supports cardiovascular risk reduction)
- •You prefer the more established compound
- •Cost is a significant factor (compounded Semaglutide is widely available)
Choose Tirzepatide if…
- •You want maximum weight loss efficacy
- •You have not achieved adequate results with Semaglutide
- •You are comfortable with a newer compound with strong but shorter clinical track record
- •You have Type 2 diabetes with poor glycemic control
Consider Both If…
You are unsure — consult with a telehealth provider who can assess your specific metabolic profile and recommend the appropriate starting point.
Frequently Asked Questions
More Comparisons
BPC-157 vs TB-500
BPC-157 excels at localized tendon, ligament, and gut healing. TB-500 is better for systemic muscle recovery and widespread inflammation.
Ipamorelin vs CJC-1295
Ipamorelin and CJC-1295 work through complementary mechanisms and are almost always used together rather than as alternatives.
Ozempic vs Wegovy
Ozempic and Wegovy both contain Semaglutide. The difference is FDA indication and maximum dose — Wegovy is approved for weight management at higher doses.
Mounjaro vs Zepbound
Mounjaro and Zepbound both contain Tirzepatide. Mounjaro is approved for Type 2 diabetes; Zepbound for obesity. The active ingredient is identical.
Selank vs Semax
Selank is primarily anxiolytic — it reduces anxiety and improves mood. Semax is primarily a cognitive enhancer — it boosts focus, memory, and BDNF. They are frequently combined.
Epithalon vs GHK-Cu
Epithalon targets cellular aging through telomere maintenance. GHK-Cu addresses visible aging through collagen synthesis and tissue remodeling. They work through complementary mechanisms.